National Cancer Institute - NCI Division of Cancer Treatment and ...
National Cancer Institute - NCI Division of Cancer Treatment and ... National Cancer Institute - NCI Division of Cancer Treatment and ...
Office. The purpose of the Roadmap Initiatives is to identify major opportunities and gaps in biomedical research that no single Institute at NIH could tackle alone but that the agency as a whole must address to make the biggest impact on the progress of medical research. Where do I go if I need ■ Funding ■ Samples for my research Individual compounds, compound libraries, natural product extracts, animal and human cell lines, biologic reference reagents ■ Routine screening for my compounds In vitro cell line screen, anti-HIV screen ■ Downloadable data In vitro 60 cell line results, in vitro anti-HIV results, yeast assay, 200,000+ chemical structures, molecular targets, microarray data I need more information about how DTP conducts ■ In vivo testing ■ Biopharmaceutical production ■ Pharmacology and toxicology testing ■ Formulation ■ Clinical batch production NIH RAID is not a grant program. Successful projects will gain access to the government’s resources as well as assistance of the NIH in establishing and implementing a product development plan. Developmental Therapeutics Program Reference Guide for New Users http://dtp.nci.nih.gov/guide.jsp Can DTP help me if ■ I need help synthesizing small quantities of compounds (R·A·N·D) ■ I need an assay developed for high throughput (R·A·N·D) ■ I want to file my own IND but I need formulation, pharmacology, toxicology, GMP production, etc. (RAID) ■ I would like to see if NCI is interested in testing my agent in an NCI-sponsored clinical trial (DDG) What if DTP doesn’t have what I need, is there any other part of NCI that can help? ■ NCI Research Resources ■ Resources for NIH Intramural Researchers I still have questions about DTP ■ Call (301) 435-9160 or e-mail our Help Desk (dtpinfo@mail.nih.gov). D E V E L O P M E N T A L T H E R A P E U T I C S P R O G R A M ■ 113
H I S T O R Y - M A R K I N G E V E N T 50th Anniversary Symposium and Timeline http://videocast.nih.gov/ram/ dtp112905a.ram In November 2005, DTP celebrated its 50th anniversary by inviting some of the cancer research community’s top names to a symposium on drug development. Speakers at this event, which can be viewed at the URL above, included Dr. Andrew von Eschenbach, then-director of NCI; Dr. James Doroshow, director, DCTD; NCI grantee Dr. Susan Band Horwitz, discoverer of paclitaxel’s mechanism of action; and Dr. Bruce Chabner, former director of the 114 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6 NCI Division of Cancer Treatment. A key panel discussion focused on the future role of DTP in drug development. The symposium also included a keynote speech by Dr. Vincent DeVita, former director of NCI; a poster session; and a concluding talk by DTP associate director Dr. Jerry Collins on applying the lessons of the past for future success. DTP also marked the anniversary by launching an interactive timeline recounting the organization’s involvement in drug development over the last 50 years. DTP’s timeline can be accessed at: http://dtp.nci. nih.gov/timeline/flash/index.htm.
- Page 67 and 68: Dr. Edward A. Neuwelt, Oregon Healt
- Page 69 and 70: Virtual Colonoscopy Training Collec
- Page 71 and 72: Not only does CTEP identify promisi
- Page 73 and 74: The Clinical Trials Cooperative Gro
- Page 75 and 76: of pediatric cancers and therapeuti
- Page 77 and 78: the front line treatment of chronic
- Page 79 and 80: Quick-Trials for Novel Cancer Thera
- Page 81 and 82: Industry Collaborators Agent Name 7
- Page 83 and 84: Industry Collaborators Agent Name 7
- Page 85 and 86: NCI Visuals Online, George McGregor
- Page 87 and 88: provided for use in this clinical t
- Page 89 and 90: with or without bevacizumab (NSC #
- Page 91 and 92: Oxaliplatin-Based Regimen Permits S
- Page 93 and 94: egular checkups to look for lymph-n
- Page 95 and 96: NCI Visuals Online. Human lymphoma
- Page 97 and 98: T O O L S , P R O D U C T S , A N D
- Page 99 and 100: ■ Clinical Trials Monitoring Bran
- Page 101 and 102: DTP’s staff and administered gran
- Page 103 and 104: therapeutics. Proposed exploratory
- Page 105 and 106: M A J O R O N G O I N G I N I T I A
- Page 107 and 108: National Cancer Institute. discover
- Page 109 and 110: C U R R E N T F U N D I N G O P P O
- Page 111 and 112: DTP oversees animal-production faci
- Page 113 and 114: disease can require considerable in
- Page 115 and 116: National Cancer Institute. commerci
- Page 117: The Type 1 Diabetes Rapid Access to
- Page 121 and 122: With this approach, patients are no
- Page 123 and 124: This included a camptothecin deriva
- Page 125 and 126: RRP supports research involving a v
- Page 127 and 128: Laredo Medical Center, Laredo, TX h
- Page 129 and 130: With TELESYNERGY® as a link, healt
- Page 131 and 132: Radiation Bioterrorism Research and
- Page 133 and 134: Enhanced Radiosensitivity The Molec
- Page 135 and 136: M E E T I N G S A N D W O R K S H O
- Page 137 and 138: Cancer Imaging Program 132 ■ P R
- Page 139 and 140: Cancer Therapy Evaluation Program,
- Page 141 and 142: Developmental Therapeutics Program,
- Page 143 and 144: Developmental Therapeutics Program,
H I S T O R Y - M A R K I N G E V E N T<br />
50th Anniversary Symposium<br />
<strong>and</strong> Timeline<br />
http://videocast.nih.gov/ram/<br />
dtp112905a.ram<br />
In November 2005, DTP celebrated its 50th<br />
anniversary by inviting some <strong>of</strong> the cancer<br />
research community’s top names to a<br />
symposium on drug development. Speakers<br />
at this event, which can be viewed<br />
at the URL above, included Dr. Andrew<br />
von Eschenbach, then-director <strong>of</strong> <strong>NCI</strong>;<br />
Dr. James Doroshow, director, DCTD; <strong>NCI</strong><br />
grantee Dr. Susan B<strong>and</strong> Horwitz, discoverer<br />
<strong>of</strong> paclitaxel’s mechanism <strong>of</strong> action; <strong>and</strong><br />
Dr. Bruce Chabner, former director <strong>of</strong> the<br />
114 ■ P R O G R A M A C C O M P L I S H M E N T S 2 0 0 6<br />
<strong>NCI</strong> <strong>Division</strong> <strong>of</strong> <strong>Cancer</strong> <strong>Treatment</strong>. A key<br />
panel discussion focused on the future<br />
role <strong>of</strong> DTP in drug development. The symposium<br />
also included a keynote speech by<br />
Dr. Vincent DeVita, former director <strong>of</strong> <strong>NCI</strong>;<br />
a poster session; <strong>and</strong> a concluding talk by<br />
DTP associate director Dr. Jerry Collins on<br />
applying the lessons <strong>of</strong> the past for future<br />
success.<br />
DTP also marked the anniversary by<br />
launching an interactive timeline recounting<br />
the organization’s involvement in drug<br />
development over the last 50 years. DTP’s<br />
timeline can be accessed at: http://dtp.nci.<br />
nih.gov/timeline/flash/index.htm.
Change language